POSTGRADUATE INSTITUTE FOR MEDICINE
"New Therapies for Anemia Management in CKD
An Interactive Symposium on the Full Spectrum of Kidney Disease"
Post-Test Answer Sheet and Evaluation Form

Please mark and submit your answers on the Post-Test / Evaluation Form . Do NOT mark your answers on this page and please do not submit your answers marked on this page to PIM.


  1. Which of the following statements about chronic kidney disease (CKD) is not true?
    1. CKD is a major public health problem.
    2. Only severe disease is a risk factor for death.
    3. Morbidity and resource utilization is high.
    4. Suboptimal care contributes to the high resource utilization.

  2. Which of the following statements about anemia of CKD is true?
    1. Anemia begins early in CKD.
    2. Anemia is an important predictor of cardiovascular disease in CKD.
    3. Anemia is an important predictor of resource utilization.
    4. Anemia is a risk factor for death.
    5. All of the above.

  3. According to data from the HCFA 2728 Form, what percent of chronic dialysis patients in the US received erythropoietin prior to starting dialysis?
    1. 8%
    2. 23%
    3. 31%
    4. 45%

  4. Prior to initiation of dialysis, the primary reason for hospitalization is ______ .
    1. ischemic heart disease
    2. infection
    3. congestive heart failure
    4. none of the above

  5. Consistent pre-ESRD rHuEPO treatment is associated with
    1. higher hematocrit levels
    2. fewer hospitalizations for cardiac disease
    3. lower total expenditures associated with the transition period
    4. all of the above

  6. Many risk factors for cardiovascular disease are the same as those that contribute to progression of kidney disease.
    1. True
    2. False

  7. Patients with severe ischemic cardiovascular disease should be aggressively treated to achieve a high hemoglobin.
    1. True
    2. False

  8. Rigatto's study found ____ to be risk factors for de novo heart failure in renal transplant patients.
    1. age
    2. systolic blood pressure
    3. hemoglobin
    4. all of the above
    5. b and c

  9. Anemia is associated with ___ .
    1. measurable changes in LVH
    2. coronary artery disease
    3. congestive heart failure
    4. all of the above
    5. a and c

  10. According the World Health Organization, anemia should be defined relative to the disease state the patient has.
    1. True
    2. False

  11. Which of the following statements about the half-life of darbepoetin alfa is true?
    1. If given intravenously, the half-life is 25 hours.
    2. If given subcutaneously, the half-live is 25 hours.
    3. If given subcutaneously, the half-live is 48 hours.
    4. a and c
    5. a and b

  12. The three most common adverse events seen in controlled clinical trials of darbepoetin alfa (hypertension, infection, and hypotension) are ____ adverse events with rHuEPO.
    1. less frequent than
    2. comparable to
    3. more frequent than